Published in Cancer Weekly, April 2nd, 2002
The study, along with two other studies in advanced CML phases, resulted in the drug's approval in one of the fastest reviews ever for a cancer therapy by the U.S. Food and Drug Administration (FDA) in May 2001.
Dr. Hagop Kantarjian, professor and chairman of M.D. Anderson's department of leukemia is the lead author of the international study, which is published in the February 28, 2002, issue of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.